BioAge Labs, Inc
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment o… Read more
BioAge Labs, Inc (BIOA) - Total Assets
Latest total assets as of September 2025: $305.09 Million USD
Based on the latest financial reports, BioAge Labs, Inc (BIOA) holds total assets worth $305.09 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioAge Labs, Inc - Total Assets Trend (2013–2024)
This chart illustrates how BioAge Labs, Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BioAge Labs, Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
BioAge Labs, Inc's total assets of $305.09 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how BioAge Labs, Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioAge Labs, Inc's current assets represent 99.7% of total assets in 2024, an increase from 83.2% in 2013.
- Cash Position: Cash and equivalents constituted 98.9% of total assets in 2024, up from 73.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
BioAge Labs, Inc Competitors by Total Assets
Key competitors of BioAge Labs, Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
BioAge Labs, Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BioAge Labs, Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BioAge Labs, Inc is currently not profitable relative to its asset base.
BioAge Labs, Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.87 | 17.63 | 1.21 |
| Quick Ratio | 11.87 | 17.63 | 1.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $266.33 Million | $ 317.39 Million | $ 5.37 Million |
BioAge Labs, Inc - Advanced Valuation Insights
This section examines the relationship between BioAge Labs, Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.09 |
| Latest Market Cap to Assets Ratio | 1.64 |
| Asset Growth Rate (YoY) | 1281.9% |
| Total Assets | $358.23 Million |
| Market Capitalization | $587.63 Million USD |
Valuation Analysis
Above Book Valuation: The market values BioAge Labs, Inc's assets above their book value (1.64 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: BioAge Labs, Inc's assets grew by 1281.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BioAge Labs, Inc (2013–2024)
The table below shows the annual total assets of BioAge Labs, Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $358.23 Million | +1281.86% |
| 2023-12-31 | $25.92 Million | -8.81% |
| 2022-12-31 | $28.43 Million | -59.10% |
| 2017-12-31 | $69.51 Million | -56.91% |
| 2016-12-31 | $161.33 Million | +12.75% |
| 2015-12-31 | $143.09 Million | -6.14% |
| 2014-12-31 | $152.44 Million | +33.63% |
| 2013-12-31 | $114.08 Million | -- |